Home Alzheimer’s Disease Atezolizumab Survival Advantage Continues To Be Seen in Frontline PD-L1–High NSCLC

Atezolizumab Survival Advantage Continues To Be Seen in Frontline PD-L1–High NSCLC

Continued follow-up of the phase 3 IMpower110 trial (NCT02409342) indicated that clinically meaningful survival and response benefit was maintained with frontline atezolizumab (Tecentriq) versus chemotherapy in patients with PD-L1–high, wild-type (WT) nonsquamous or squamous non–small cell lung cancer (NSCLC). Findings from the updated analysis that included a review of overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and duration of response (DOR) end points were presented during the 2020 World Conference on Lung Cancer Singapore.1

With a median follow up of 31.3 months, the median OS was 20.2 months with atezolizumab (n = 107) versus 14.7 months with chemotherapy (n = 98) in the high PD-L1 expression WT group. The 6-month OS rate was 76.5% versus 70.4%, respectively. The 12-month OS rate was 66.1% versus 52.3%, respectively (HR, 0.76; 95% CI,…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Treatment with PARP Inhibitors Increased Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Patients treated with PARP inhibitors saw an increased risk of myelodysplastic syndrome and acute myeloid leukemia (AML) versus patients treated with placebo, according to...

Recent Comments